In addition, IFN-β treatment decreases the expression of CCR5 on T cells from MS patients, and in vitro treatment of T cells with IFN-β inhibits the expression of this chemokine receptor and its ligands, including CCL5 and CCL3 (Zang et al., 2001). This evidence concerns the gene CCL5 and myeloid sarcoma.